What Is Claimed Is:

1. A method for the identification of an agent to be used in the treatment of AD, wherein said agent is capable of altering the production of Cu(I) by Aβ, said method comprising:

(a) adding Cu(II) to a first Aβ sample;

(b) allowing said first sample to incubate for an amount of time sufficient to allow said first sample to generate Cu(I);

(c) adding Cu(II) to a second Aβ sample, said second sample additionally comprising a candidate pharmacological agent;

(d) allowing said second sample to incubate for the same amount of time as said first sample;

(e) determining the amount of Cu(I) produced by said first sample and said second sample; and

(f) comparing the amount of Cu(I) produced by said first sample to the amount of Cu(I) produced by said second sample;

whereby a difference in the amount of Cu(I) produced by said first sample as compared to said second sample indicates that said candidate pharmacological agent has altered the production of Cu(I) by Aβ.

2. The method of claim 1, wherein the amount of Cu(I) present in said first and said second sample is determined by

(a) adding a complexing agent to said first and said second sample, wherein said complexing agent is capable of combining with Cu(I) to form a complex compound, wherein said complex compound has an optimal visible absorption wavelength;

(b) measuring the absorbancy of said first and said second sample; and

(c) calculating the concentration of Cu(I) in said first and said second sample using the absorbancy obtained in step (b).

3. The method of claim 2, wherein said complexing agent is bathocuproinedisulfonic anion.

4. The method of claim 2 or claim 3, wherein said method is performed in a microtiter plate, and the absorbancy measurement is performed by a plate reader.

5. The method of claim 4, wherein two or more different test candidate agents are simultaneously evaluated for an ability to alter the production of Cu(I) by Aβ.

6. The method of claim 1, wherein said first Aβ sample of step 1(a) and said second Aβ sample of step 1(c) is a biological sample.

7. The method of claim 6, wherein said biological sample is CSF.

8. A method for the identification of an agent to be used in the treatment of AD, wherein said agent is capable of altering the production of Fe(II) by Aβ, said method comprising:

(a) adding Fe(III) to a first Aβ sample;

(b) allowing said first sample to incubate for an amount of time sufficient to allow said first sample to generate Fe(II);

(c) adding Fe(III) to a second Aβ sample, said second sample additionally comprising a candidate pharmacological agent;

(d) allowing said second sample to incubate for the same amount of time as said first sample;

(e) determining the amount of Fe(II) produced by said first sample and said second sample; and

(f) comparing the amount of Fe(II) present in said first sample to the amount of Fe(II) present in said second sample;

whereby a difference in the amount of Fe(II) present in said first sample as compared to said second sample indicates that said candidate pharmacological agent has altered the production of Fe(II) by Aβ.

9. The method of claim 8, wherein the amount of Fe(II) present in said first and said second sample is determined by

(a) adding a complexing agent to said first and said second sample, wherein said complexing agent is capable of combining with Fe(II) to form a complex compound, wherein said complex compound has an optimal visible absorption wavelength;

(b) measuring the absorbancy of said first and said second sample; and

(c) calculating the concentration of Fe(II) in said first and said second sample using the absorbancy obtained in step (b).

10. The method of claim 9, wherein said complexing agent is bathophenanthrolinedisulfonic (BP) anion.

11. The method of claim 9 or claim 10, wherein said method is performed in a microtiter plate, and the absorbancy measurement is performed by a plate reader.

12. The method of claim 11, wherein two or more different test candidate agents are simultaneously evaluated for an ability to alter the production of Fe(II) by Aβ.

13. The method of claim 8, wherein said first Aβ sample of step 1(a) and said second Aβ sample of step 1(c) is a biological sample.

14. The method of claim 13, wherein said biological sample is CSF.

15. A method for the identification of an agent to be used in the treatment of AD, wherein said agent is capable of altering the production of H_2O_2 by Aβ, said method comprising:

(a) adding Cu(II) or Fe(III) to a first Aβ sample;

(b) allowing said first sample to incubate for an amount of time sufficient to allow said first sample to generate H_2O_2;

(c) adding Cu(II) or Fe(III) to a second Aβ sample, said second sample additionally comprising a candidate pharmacological agent;

(d) allowing said second sample to incubate for the same amount of time as said first sample;

(e) determining the amount of H_2O_2 produced by said first sample and said second sample; and

(f) comparing the amount of H_2O_2 present in said first sample to the amount of H_2O_2 present in said second sample;

whereby a difference in the amount of H_2O_2 present in said first sample as compared to said second sample indicates that said candidate pharmacological agent has altered the production of H_2O_2 by Aβ.

16. The method of claim 15, wherein the Aβ samples of steps (a) and step (b) are a biological fluid.

17. The method of claim 16, wherein said biological fluid is CSF.

18. The method of claim 15, wherein the determination of step (e) of the amount of H_2O_2 present in said first and said second sample is determined by

(a) adding catalase to a first aliquot of said first sample obtained in step (a) of claim 1 in an amount sufficient to break down all of the H_2O_2 generated by said sample;

(b) adding TCEP, in an amount sufficient to capture all of the H_2O_2 generated by said samples, to

(i) said first aliquot

(ii) a second aliquot of said first sample obtained in step (a) of claim 1; and

(iii) said second sample obtained in step (b) of claim 1;

(c) incubating the samples obtained in step (b) for an amount of time sufficient to allow the TCEP to capture all of the H_20_2;

(d) adding DTNB to said samples obtained in step (c);

(e) incubating said samples obtained in step (d) for an amount of time sufficient to generate TMB;

(f) measuring the absorbancy at 412 nm of said samples obtained in step (e); and

(g) calculating the concentration of H_2O_2 in said first and said second sample using the absorbancies obtained in step (f).

19. The method of claim 18, wherein said method is performed in a microtiter plate, and the absorbancy measurement is performed by a plate reader.

20. The method of claim 19, wherein two or more different test candidate agents are simultaneously evaluated for an ability to alter the production of H_2O_2 by Aβ.

21. A method for the identification of an agent to be used in the treatment of AD, wherein said agent is capable of decreasing the production of O_2- by Aβ, said method comprising:

(a) adding Aβ and to a first buffer sample having an O_2 tension greater than 0;

(b) allowing said first sample to incubate for an amount of time sufficient to allow said first sample to generate O_2-;

(c) adding Aβ and a candidate pharmacological agent to a second buffer sample having an O_2 tension greater than 0;;

(d) allowing said second sample to incubate for the same amount of time as said first sample;

(e) determining the amount of O_2- produced by said first sample and said second sample; and

(f) comparing the amount of O_2- present in said first sample to the amount of O_2- present in said second sample;

whereby a difference in the amount of O_2- present in said first sample as compared to said second sample indicates that said candidate pharmacological agent has altered the production of O_2- by Aβ.

22. The method of claim 21, wherein said Aβ is $A\beta_{1-42}$.

23. The method of claim 21, wherein the determination of the amount of O_2- present in said samples is accomplished by measuring the absorbancy of the sample at about 250 nm.

24. A method for the identification of an agent to be used in the treatment of AD, wherein said agent is capable of interfering with the interaction of O_2 and Aβ to produce O_2-, without interfering with the SOD-like activity of Aβ, said method comprising:

(a) identifying an agent capable of decreasing the production of O_2- by Aβ; and

(b) determining the ability of said agent to alter the SOD-like activity of Aβ.

25. The method of claim 24, wherein the determination of the ability of said agent to alter the SOD-like activity of Aβ is made by determining whether Aβ is capable of catalytically producing Cu(I), Fe(II) or H_2O_2.

26. A method for the identification of an agent to be used in the treatment of AD, wherein said agent is capable of reducing the toxicity of Aβ, said method comprising:

(a) adding Aβ to a first cell culture;

(b) adding Aβ to a second cell culture, said second cell culture additionally containing a candidate pharmacological agent;

(c) determining the level of neurotoxicity of Aβ in said first and said second samples; and

(d) comparing the level of neurotoxicity of Aβ in said first and said second samples,

whereby a lower neurotoxicity level in said second sample as compared to said first sample indicates that said candidate pharmacological agent has reduced the neurotoxicity of Aβ, and is thereby capable of being used to treat AD.

27. The method of claim 26, wherein the neurotoxicity of Aβ is determined by using an MTT assay.

28. The method of claim 26, wherein the neurotoxicity of Aβ is determined by using an LDH release assay.

29. The method of claim 26, wherein the neurotoxicity of Aβ is determined by using a Live/Dead assay.

30. The method of claim 26, wherein said cells are rat cancer cells.

31. The method of claim 26, wherein said cells are rat primary frontal neuronal cells.

32. A kit for determining whether an agent is capable of altering the production of Cu(I) by Aβ which comprises a carrier means being

compartmentalized to receive in close confinement therein one or more container means wherein

(a) the first container means contains a peptide comprising Aß peptide;

(b) a second container means contains a Cu(II) salt; and

(c) a third container means contains BC anion.

33. The kit of claim 32, wherein said Aβ peptide is present as a solution in an aqueous buffer or a physiological solution, at a concentration above about 10 μM.

34. A kit for determining whether an agent is capable of altering the production of Fe(II) by Aβ which comprises a carrier means being compartmentalized to receive in close confinement therein one or more container means wherein

(a) the first container means contains a peptide comprising Aß peptide;

(b) a second container means contains an Fe(III) salt; and

(c) a third container means contains BP anion.

35. The kit of claim 34, wherein said Aβ peptide is present as a solution in an aqueous buffer or a physiological solution, at a concentration above about 10 μM.

36. A kit for determining whether an agent is capable of altering the production of H_2O_2 by Aβ which comprises a carrier means being compartmentalized to receive in close confinement therein one or more container means wherein

(a) the first container means contains a peptide comprising Aß peptide;

(b) a second container means contains a Cu(II) salt;

(c) a third container means contains TCEP; and

(d) a fourth container means contains DTNB.

37. The kit of claim 36, wherein said Aβ peptide is present as a solution in an aqueous buffer or a physiological solution, at a concentration above about 10 μM.

38. A method for the identification of an agent to be used in the treatment of AD, wherein said agent is capable of inhibiting redox-reactive metal -mediated crosslinking Aβ, said method comprising:

(a) adding a redox-reactive metal to a first Aβ sample;

(b) allowing said first sample to incubate for an amount of time sufficient to allow Aβ crosslinking;

(c) adding said redox-reactive metal to a second Aβ sample, said second sample additionally comprising a candidate pharmacological agent;

(d) allowing said second sample to incubate for the same amount of time as said first sample;

(e) removing an aliquot from each of said first and said second sample; and

(f) determining presence or absence of crosslinking in said first and second samples,

whereby an absence of Aβ crosslinking in said second sample as compared to said first sample indicates that said candidate pharmacological agent has inhibited Aβ crosslinking.

39. The method of claim 38, wherein at step (f), a western blot analysis is performed to determine the presence or absence of crosslinking in the first and the second sample.